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Abstract
Background Primary immunodeficiency disorders (PID) are a
group of heterogeneous disorders mainly characterized by
severe and recurrent infections and increased susceptibility
to malignancies, lymphoproliferative and autoimmune
conditions. National registries of PID disorders provide epi-
demiological data and increase the awareness of medical
personnel as well as health care providers.
Methods This study presents the demographic data and clin-
ical manifestations of Iranian PID patients who were
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diagnosed from March 2006 till the March of 2013 and were
registered in Iranian PID Registry (IPIDR) after its second
report of 2006.
Results A total number of 731 new PID patients (455 male
and 276 female) from 14 medical centers were enrolled in the
current study. Predominantly antibody deficiencies were the
most common subcategory of PID (32.3 %) and were follow-
ed by combined immunodeficiencies (22.3 %), congenital
defects of phagocyte number, function, or both (17.4 %),
well-defined syndromes with immunodeficiency (17.2 %),
autoinflammatory disorders (5.2 %), diseases of immune dys-
regulation (2.6 %), defects in innate immunity (1.6 %), and
complement deficiencies (1.4 %). Severe combined immuno-
deficiency was the most common disorder (21.1 %). Other
prevalent disorders were common variable immunodeficiency
(14.9 %), hyper IgE syndrome (7.7 %), and selective IgA
deficiency (7.5 %).
Conclusions Registration of Iranian PID patients increased
the awareness of medical community of Iran and developed
diagnostic and therapeutic techniques across more parts of the
country. Further efforts must be taken by increasing the cov-
erage of IPIDR via electronically registration and gradual
referral system in order to provide better estimation of PID
in Iran and reduce the number of undiagnosed cases.
Keywords Epidemiology . infection . Iran . primary
immunodeficiency
Introduction
Primary immunodeficiency disorders (PID) are a heteroge-
neous group of hereditary defects in the development or the
function of immune system [1–4]. PID patients are more
likely to experience recurrent and/or severe infections and
have a tendency to immunologic complications [5–8]. Since
the identification of the first PID in 1952, more than 220 types
of these disorders have been described in the literature [9, 10].
The increasing number of known types of PID in the past two
decades is mainly due to the increasing knowledge regarding
the function of immune system in addition to more accurate
molecular and genetic diagnostic methods [11, 12]. Lack of
awareness on PIDs in physicians, is the major reason in
delayed diagnosis and inadequate treatment resulting in mor-
bidity and mortality [13–15].
PID has been generally considered as rare disorders world-
wide [12]. However, according to epidemiologic studies, the
true incidence and prevalence of PID are enormously
underestimated due to the lack of effective and available
screening tests and it may affect around six million individuals
at its upper estimation [12]. Registry reports of several coun-
tries show wide variations in geographical and racial preva-
lence as well as the frequency of different types of PID [12,
16]. Moreover, these data provide epidemiological informa-
tion as well as increasing the awareness of physicians and
health care system strategists [11].
Iranian Primary Immunodeficiency Registry (IPIDR) was
established in August 1999 with the main aim of determining
the prevalence of various types of PID in Iran [11]. The first
registry report of Iran was published in 2002 consisted of 440
PID patients with primary antibody deficiencies as the most
common group of these disorders [17]. The second report was
published in 2006 included 930 patients (490 new cases) with
similarities in the prevalence of different groups of PID in the
first report [11]. This study presents the demographic and
clinical presentation of Iranian PID patients who were diag-
nosed and registered in IPIDR from 14 participant medical
centers between March 2006 and March 2013.
Patients and Methods
Iranian Primary Immunodeficiency Registry (IPIDR)
The main aim of IPIDR was to provide epidemiological data
of PID in Iran. By the March of 2006, 930 PID patients from
different provinces of the country were registered in IPIDR
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during a 30 years period of time and 731 new patients were
registered from March 2006 till March 2013.
By the last estimation in 2011, Iran has a population of
75,669,750 registered Iranian citizens and an additional
1.959,000 citizens of other countries mainly refugees from its
neighbor countries such as Afghanistan and Iraq. In addition to
Iranian citizens, all PID cases who were a resident of Iran at the
time of birth and diagnosis were also registered in IPIDR. The
process of this study as well as data entry, analysis and reporting
of IPIDR was approved by Ethics Committee of Tehran Uni-
versity of Medical Science. Moreover, all patients who entered
this registry, or their parents or legal guardians, if need, were
asked to fill an informed consent guaranteeing patients’ names
and personal data won’t be published under any circumstances.
Patients’ Enrollment
The diagnosis of PID patients was made according to the criteria
of Pan-American Group for Immunodeficiency (PAGID),
European society for immunodeficiencies (ESID) and the
International Union of Immunological Societies (IUIS), between
March 2006 and March 2013[18]. Secondary defects of immune
system such asHIVinfectionwere ruled out by the use of standard
tests in all cases. Laboratory evaluations were performed in the
study group as indicated including immunoglobulin serum levels,
IgG subtypes serum level, isohemagglutinin tests, assessment of
post-vaccination serum antibody response such as anti-tetanus,
anti-diphtheria and anti-pneumococcal, flow cytometry evaluation
of lymphocyte subtypes, chemotaxis studies, nitro blue tetrazoli-
um dye test, granulocyte function tests, complement component
and hemolytic titration of complement (C3, C4, CH50), andDNA
mutation analysis for diagnosis confirmation [11].
Participant Centers
Registry database is located in Children’s Medical Center
(Tehran, Iran) which serves as a referral hospital for suspected
or diagnosed cases of PID. In addition, 14 medical centers
affiliated to 13 medical science universities collaborated in the
registry program from 13major states of the country including
Tehran, Azerbaijan, Khorasan, Isfahan, Fars, Gilan,
Mazandaran, Khuzestan, Yazd, Golestan, Qazvin, Ardabil
and Sistan and Baluchestan (Fig. 1). All of the participated
centers had access to mandatory laboratory equipments for
immunological evaluation of patients according to the stan-
dard diagnostic approaches. It should be mentioned that cases
with suspected diagnosis were referred and re-evaluated in
Children’s Medical Center for definitive diagnosis.
Data Collection
All data were provided by the same immunologists who
were at the charge of patients’ diagnosis and clinical
care. Participant medical centers have been given the
choice to register their patients by either the online
access or the old paper and pencil method. In the online
method, every participant immunologist has been given
a user name and password at the registry website by
using the following address: http://rcid.tums.ac.ir/.
Participants could use their limited access for entering
the diagnosis and demographic data of their patients.
After reviewing the cases by the administrator of the
system for duplicated or old cases, participants were
able to enter the family history, clinical features,
laboratory data, and paraclinical findings of the
patients as well as the follow-up information of their
patients.
In the second method, the following steps were made:
Participants were asked to fill a one-page preliminary ques-
tionnaire including the diagnosis and the demographic data for
each patient. After the primary review by secretary for elim-
ination of duplicated or old cases, another four-page question-
naire was sent and the centers were asked to complete clinical
features, laboratory data, and paraclinical findings of their
patients as well as the follow-up information. After recheck
for probable mistakes, all reported cases provided by the both
methods were reviewed by the head of the registry program
and then included in the database if they met the standard
diagnostic criteria.
Database
All data, both sent by online method or paper questionnaire,
were finally gathered at our online database with the ability to
convert all desired parameters to Microsoft Excel 2010 data
files (Microsoft, USA). All information were converted and
saved in Excel data files after any change in the online
database to prevent unexpected data loss. Participated physi-
cians were able to access the full information of their own
patients but were not allowed to see the data sent by other
physicians or make any change in their own cases before the
approval of system’s administrator. Online database was up-
dated frequently and all follow-up data sent by the end of the
study period were included. For ethical considerations, pa-
tients’ names in database were replaced with codes before
analysis.
Statistical Analysis
Data were collected in Excel database and were converted for
analysis using the SPSS statistical software package version
19.0 (IBM corporation, USA). Linear regression analysis was
performed to evaluate the chronological effect of time on the
different parameters. A p-value lower than 0.05 was consid-
ered statistically significant.
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Results
Patients’ Characteristics and Distribution of PID
A total number of 731 PID patients (455male and 276 female)
from 14 medical centers were enrolled in the study in the time
period betweenMarch 2006 andMarch 2013. Thirty-six types
of diagnoses were made in the population study which was
included into 8 groups of PID disorders according to the IUIS
classification. Predominantly antibody deficiencies were the
most common group of PID affecting 236 patients (32.3 %)
and were followed by combined immunodeficiencies in 163
cases (22.3 %), congenital defects of phagocyte number,
function, or both in 127 cases (17.4 %), well-defined syn-
dromes with immunodeficiency in 126 cases (17.2 %),
autoinflammatory disorders in 38 cases (5.2 %), diseases of
immune dysregulation in 19 cases (2.6 %), defects in innate
immunity in 12 cases (1.6 %), and complement deficiencies in
10 cases (1.4 %). Figure 2 shows the share of each PID
groups.
Severe combined immunodeficiency (SCID) was the most
common specific disorder consisting of 154 cases (21.1 %).
Other prevalent disorders were common variable immunode-
ficiency (CVID) in 109 cases (14.9 %), hyper IgE syndrome
(HIgE) in 56 cases (7.7 %), selective IgA deficiency in 55
cases (7.5 %), ataxia-telangiectasia (AT) in 52 cases (7.1 %),
chronic granulomatous disease (CGD) in 51 cases (7 %),
Familial Mediterranean fever (FMF) in 37 cases (5.1 %), X-
linked agammaglobulinemia (XLA) in 33 cases (4.5 %), se-
vere congenital neutropenia in 31 cases (4.2 %), leukocyte
Fig. 1 Schematic map of Iran indicating cumulative incidence of PID during the last 7 years (per million) in each state
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adhesion deficiency (LAD) in 29 cases (4 %), hyper IgM
syndrome (HIgM) in 28 cases (3.8 %), Wiskott-Aldrich syn-
drome in 16 cases (2.2 %), Mendelian susceptibility of myco-
bacterial disease (MSMD) and hereditary angioedema each in
10 cases (1.4 %). The prevalence of other disorders consisting
of less than 10 patients is summarized in Table I.
Geographical Distribution
Of 731 PID patients, 724 (99 %) had Iranian citizenship while
5 cases (0.7 %) had Iraqi citizenship, 1 case (0.1 %) had Tajik
citizenship and another one (0.1 %) had Afghan citizenship,
while all were the inhabitants of Iran. The approximate num-
ber of diagnosed cases of PID in each year was 104 without
any significant difference during the past 7 years. The cumu-
lative incidence of PID is about 9.7 per 1,000,000 populations
during the last 7 years, with a regional variation from 1 to 22.4
per 1,000,000 populations. Of 731 cases, 327 (44.7 %) were
living in Tehran province mainly in Tehran, the capital of the
country. About 19 % of the country’s population lives in this
province. Other provinces with high number of registered PID
patients were north provinces including Azerbaijan in north
west (16.1 %), Isfahan in center (7.5 %), and Khorasan in
north east (7 %). There was significantly lower number of
registered cases in west and south east provinces which was
accompanied with a lack of participant medical centers in
these provinces (Fig. 1). The number and the cumulative
incidence of PID in various provinces of the country during
the past 7 years are summarized in Table II.
Age Distribution and Diagnostic Delay
The median age of the patients at the end of the study was
8 years ranged from 2 months to 56 years. The median age of
the patients at the onset of disease was 1 year ranged from
shortly after birth to 40 years. One hundred and nineteen out
of 731 cases (16.3 %) experienced the first symptom before
the age of 1 month and 406 cases (55.5 %) showed the first
symptom by the age of 1 year. Only 30 out of 731 cases
(4.1%) showed the first manifestation of disease after 14 years
of age. This included, most notably, 8 patients with hereditary
angioedema (80 % of cases), 12 patients with CVID (11 % of
cases), and 5 patients with hyper-IgE syndrome (9% of cases).
The median age of the patients at the time of diagnosis was
3 years and 6 months ranged from 1 month to 51 years. The
median diagnostic delay was 1 year ranged from 0 to 28 years.
The highest diagnostic delay was observed in a CVID patient
who suffered from diarrhea from 28 years prior to the diag-
nosis. Of 731 cases, diagnosis was made in 380 (52 %) within
1 year from the onset of disease and within 2 years from the
onset of disease in 475 cases (65 %). Diagnostic delay was
higher than 5 years only in 129 cases (17.6 %). Highest
diagnostic delay was observed among patients with MHC II
deficiency (median, 6.04 years), followed by NEMOdeficien-
cy (median, 6 years), Dock8 deficiency (median, 5 years), and
CVID (median, 4 years). Patients’ demographic data are sum-
marized in Table I. There was a direct association between the
age of the patients at the onset of disease and diagnostic delay
(r=0.012, F=4.767, P=0.03). The same kind of association
was observed between the current age of patients and diag-
nostic delay (r=0.289,F=154.707,P<0.001). Figure 3 shows
diagnostic delay in population study based on the age of the
patients at the onset of disease and the current age of patients
respectively.
Family History and Consanguinity
A family history of PID was found in 126 cases (17.2 %).
Family history of recurrent infections without a known diag-
nosis of PID was positive in 86 cases (11.7 %). In 191 cases
(26.1 %), a positive family history of death at an early age was
documented. A history of diagnosed cancer was reported in
the family of 36 patients (4.9 %); and 46 individuals (6.2 %)
revealed a positive family history for autoimmune disorders.
Consanguineous marriage was observed in the parents of
461 cases (63.1 %). There was a significant difference be-
tween the consanguinity rates of various types of PID. Paren-
tal consanguinity was most common in diseases of immune
dysregulation and combined immunodeficiencies and was
observed in 100 % (19 out of 19 cases) and 71.2 % (116 out
of 163 cases) of cases with these groups of PID respectively.
In contrast, patients with complement deficiencies and
22.3
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Combined immunodeficiencies
Well-defined syndromes with
immunodeficiency
Predominantly antibody deficiencies
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Fig. 2 Prevalence of different
types of PID in the study group
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autoinflammatory disorders had the lowest consanguinity rate
with 40 % (4 out of 10 cases) and 39.5 % (15 out of 38 cases)
respectively. Table I shows consanguinity rate among various
groups and types of PID.
First Presentation
The most common first presentation of PID patients was pneu-
monia observed in 171 cases (23.4 %). It was followed by
eczema and itching in 54 cases (7.4 %), diarrhea in 52 cases
(7.1 %), ataxic gait in 50 cases (6.8 %), omphalitis and/or
delayed umbilical cord detachment in 50 cases (6.8 %), otitis
media in 46 cases (6.3 %), recurrent sinusitis in 35 cases
(4.8 %), other upper respiratory tract infections in 39 cases
(5.3 %), episodic fever and abdominal pain in 37 (5.1 %),
superficial abscesses in 35 cases (4.8 %), lymphadenop-
athy in 15 cases (2.1 %), mucocutaneous candidiasis in
25 cases (3.4 %), BCGosis in 17 cases (2.3 %), swell-
ing in various parts of skin in 10 cases (1.4 %), other
cutaneous manifestations in 37 (5 %), failure to thrive
in 7 cases (1 %). Other presenting features which were
observed in less than 5 cases including fever of un-
known origin, oral lesions, bacterial and viral meningi-
tis, cellulitis, conjunctivitis, deep organ abscesses, alo-
pecia, easy bruising, gingivitis, arthralgia and septic
arthritis. Regarding the observation of rare PID compli-
cations as the presenting feature, PID was first present-
ed in one patient affected by XLA with Kawasaki dis-
ease. In addition, Hodgkin’s lymphoma was the present-
ing manifestation in one patient with AT.
Early Outcome
From 731 patients, 137 cases (18.7 %) were confirmed to be
dead (86 male and 51 female). Out of 731 cases, 114 (15.6 %)
could not be located during the last 6 months of the study
period. Beside the specific disorders with a frequency of less
than 10 cases, mortality rate was highest in combined immu-
nodeficiencies (115 SCID cases and 1 CD40 deficiency case)
with amortality rate of 71.1% (136 out of 163 cases) and lost to
follow up rate of 8.6 % (14 out of 163 cases). Four patients
(1.7 %) with predominantly antibody deficiencies (3 CVID
cases and 1 case of HIgM) and 8 patients (6.3 %) with defects
of phagocyte number, function, or both (4 cases of LAD, 1 case
of CGD, 1 case of severe congenital neutropenia, 1 Dock8
deficiency case, and 1 case of cyclic neutropenia,), 8 cases
(6.3 %) with well-defined syndromes with immunodeficiency
(3 cases of AT, 3 cases of Wiskott-Aldrich syndrome, 1 case of
hyper-IgE syndrome, and 1 case of Nijmegen syndrome), and 2
patients (13.3 %) with diseases of immune dysregulation (1
case of Chediak-Higashi syndrome, and 1 case of XLP) were
also dead by the end of the follow-up period. Cardiopulmonary
failure due to severe pneumonia and sepsis was the cause ofTa
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death in all cases except of 1 case of SCID who died from
intracranial hemorrhage, another 1 case of SCID who died of
end stage renal disease, and 1 case of Wiskott-Aldrich syn-
drome died of severe internal hemorrhage.
Total Number of Registered Iranian PID Patients
By the March of 2013, a total number of 1,661 PID
patients (1,028 male and 633 female) were registered in
IPIDR. This number includes 930 PID patients who
were diagnosed during a 30 years period of time till
the March of 2006 and 731 PID cases were diagnosed
and registered in IPIDR afterwards (Table III). The
cumulative incidence of PID in Iran during the past
10 years is estimated to be around 13 cases per
1,000,000 populations. The approximate number of di-
agnosed PID cases was reported to be 7 per year in
1980s, 30 per year 1990s, 58 per year from 2000 to the
March of 2006, and 104 per year afterwards till the
March of 2013. Figure 4 shows the number of
registered PID patients during various time periods.
Out of these 1,661 PID patients, 593 cases were diagnosed
with predominantly antibody deficiencies (35.7 %), 390 cases
(23.5 %) with congenital defects of phagocyte number, func-
tion, or both, 291 cases (17.5 %) with well-defined syndromes
with immunodeficiency, 265 cases (16 %) with combined
immunodeficiencies, 40 cases (2.4 %) with diseases of im-
mune dysregulation, 38 cases (2.3 %) with autoinflammatory
disorders, 32 cases (1.9 %) with complement deficiencies, and
12 cases (0.7 %) with defects in innate immunity. Table III
shows the prevalence of PID in reports from Europe, Latin
America and Asia.
Discussion
The current study represents the demographic data of Iranian
PID patients who were diagnosed from the March of 2006 till
the March of 2013. A total number of 731 patients were
registered in IPDR during this period. It is most likely that
Table II The frequency of diagnosed cases by province
Number of
participant
centers
No. of PID
cases (% of
total cases)
Population
(million)
% of country’s
population
Cumulative incidence
during the last 7 years
(per million)
Diagnostic delay
(years), median
(range)
Death (%)
Tehran 4 327 (44.7 %) 14.6 19 % 22.4 1 (0–28) 8.9 %
Azarbayjan (Easterm
& Western)
1 118 (16.1 %) 6.8 9 % 11.4 0(0–7) 8.5 %
Khorasan 1 51 (7 %) 7.5 10 % 6.8 4.5 (0–28) 3.9 %
Isfahan 1 55 (7.5 %) 4.9 6 % 11.2 0.44 (0–1) 3.6 %
Fars 1 36 (4.9 %) 4.6 6 % 7.8 0.75 (0–10) 11.1 %
Gilan 1 21 (2.9 %) 2.5 3 % 8.4 1 (0–9) 14.3 %
Mazandaran 2 19 (2.6 %) 3 4 % 6.3 0.8 (0–6) 15.8 %
Khuzestan 1 17 (2.3 %) 4.5 6 % 3.8 3 (0–15) 5.9 %
Lorestan 11 (1.5 %) 1.8 2 % 6.1 0.21 (0–6) 0 %
Markazi 8 (1.1 %) 1.4 2 % 5.7 1 (0–6) 12.5 %
Qom 8 (1.1 %) 1.1 1 % 7.3 2.25 (1–11) 0 %
Yazd 1 8 (1.1 %) 1 1 % 8 0.08 (0–2) 12.5 %
Golestan 1 6 (0.8 %) 1.8 2 % 3.3 1.92 (0–7) 0 %
Qazvin 1 9 (1.2 %) 1.2 2 % 7.5 4.75 (0–7) 0 %
Bushehr 5 (0.7 %) 1 1 % 5 1.5 (1–2) 0 %
Ardabil 1 5 (0.7 %) 1.2 2 % 4.2 0.91 (0–3) 20 %
Kurdestan 4 (0.5 %) 1.5 2 % 2.7 1.55 (0–3) 0 %
Hormozgan 5 (0.7 %) 1.5 2 % 3.3 2.56 (0–5) 0 %
Sistan and Baluchestan 1 2 (0.3 %) 2.5 3 % 2.8 4.5 (2–7) 0 %
Kermanshah 4 (0.5 %) 2 3 % 2 0.75 (0–1) 0 %
Kerman 3 (0.4 %) 3 4 % 1 1.25 (0–2) 0 %
Ilam 2 (0.3 %) 0.5 1 % 4 0.5 (0–1) 0 %
No Province (non-Iranian) a 7 (1 %) 2 NA 3.5 1 (0–7) 0 %
NA not applicable
a Foreign citizens are not included in the total population of the country from Iraq, Afghanistan, and Tajikistan
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this number does not reflect the prevalence and the burden of
PID in Iran due to multiple limiting factors; there is no
screening test available for PID neither at the national level
nor at any medical center; our registry system is hospital based
and voluntary and in addition to the lack of enough immunol-
ogists, there are only a limited number of medical centers
mainly in highly populated cities, which has access to sophis-
ticated diagnostic and therapeutic techniques [11]. It is possi-
ble that patients with mild manifestations may be treated by
general practitioners, pediatricians or other specialist at the
private offices or clinics. On the other hand, patients with
more severe types of PID like SCID may die before a defin-
itive diagnosis is made [11, 19, 20]. Moreover, many PID
patients may be referred and managed by other specialists
especially in the absence of severe and recurrent infections
as the main clinical presentation [21–24].
Considering the result of the current report, the distribution
of different types of PID in Iran is in agreement with other
reports from several countries. Predominantly antibody defi-
ciencies were the most common group of PID similar to the
reports of European, Latin American and some Asian regis-
tries including Japan, Korea and China [25–29]. It is notewor-
thy that these disorders were thought to be more prevalent
according to the previous reports from the Europe in 2006
(66.9 % of PID cases) [11]. However, according to the recent
reports from Europe [30], their prevalence became more sim-
ilar to the reports from Iran (56.4 vs. 32.3 % respectively).
Moreover, the percentage of Iranian PID patients with these
disorders is similar in the current report and previous registry
report of 2006 reducing the probable effect of incidental
findings. Well-defined syndromes with immunodeficiency
were the second most prevalent group of PID in most of the
previously reported registries [11, 21, 25, 27, 30–32]. How-
ever, in the current study, combined T- and B-cell immunode-
ficiencies were the second most prevalent group of PID ob-
served in 22.3 % of cases. This finding was in agreement with
the results of some PID registries of Asian countries including
Qatar, China, Kuwait, Egypt and Japan with a near share of
this disorders among their PID patients [25, 26, 31, 33, 34] but
much higher than those of Europe and Latin America [27, 30].
Congenital defects of phagocyte number, function, or both
and well-defined syndromes with immunodeficiency were the
third and fourth most common group of PID involving 17.4 %
and 17.2 % of patients respectively. This rate is similar to the
result of several reports from Asian countries including Japan,
China, Oman and Qatar [26, 32, 33] but is higher than Europe,
Latin America, and Australia [21, 27, 30] for congenital
defects of phagocyte number, function, or both and in agree-
ment to the results of almost all performed studies for the
prevalence of well-defined syndromes with immunodeficien-
cy [25–27, 30, 31, 33, 34]. In this report, 5.2 % of PID cases
were diagnosed with autoinflammatory disorders. In fact the
only study which mentioned this PID group is ESID database
representing the European PID registry (2 % of cases) [30].
This rate is higher than all of the previously reported studies
probably due to two reasons. First, autoinflammatory disor-
ders such as FMF were not recognized as a group of PID
disorders until the IUIS classification of 2011 [9]. Second, the
prevalence of such disorders, especially FMF, is mostly ob-
served in specific genetic groups with a geographical pattern
of distribution [35]. Diseases of immune dysregulation, and
complement deficiencies were the least prevalent types of
PID, a finding which was observed in most of the previously
reported studies [21, 27, 28, 30, 31, 33, 34].
SCID, CVID, hyper-IgE syndrome, and selective IgA de-
ficiency were the most observed disorders in the current study.
In contrast with the results of almost all other studies including
previous registry reports from Iran, SCID was the most prev-
alent type of PID disorders in our registered patients. This
finding is mainly due to the presence of numerous Azerbai-
janis Turks in our study population since about 16 % of cases
were registered from Azerbaijan province and it is most likely
a bFig. 3 a and b The association
between the diagnostic delay
(year) and age of patients at the
onset of disease (year) and
patients’ current age (year)
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that many other patients with this ethnicity were registered
from other provinces of the country. In a study by Shabestari
et al. on the prevalence of PID in northwest Iran, with Azer-
baijanis Turks as the main ethnic group, SCID was the most
common disorder indicating a genetic background in this
ethnicity which consists at least 24 % of Iran’s population
[36]. Hyper-IgE syndrome was the third most observed disor-
der in the current registry. The higher prevalence of this
disorder comparing to other reports is highly due to the higher
detection as a result of some published and yet to be published
studies on immunological aspects of dermatological diseases
such as severe atopic dermatitis [37]. Selective IgA deficiency
was more frequent in the registry reports of European coun-
tries [28, 30, 38], a finding which was in contrast with the
result of studies performed in Asian countries including Japan,
Iran and Australia [11, 21, 26]. The true prevalence of selec-
tive IgA deficiency may be underestimated in the mentioned
studies since they were all hospital based and asymptomatic
cases are not included [11, 39, 40]. In addition, patients with
mildmanifestationmay be treated symptomatically by general
practitioners without any referral to an immunologist or im-
munologic screening [41, 42]. In contrast, CVID patients are
more prone to severe and recurrent infections and require
IVIG replacement therapy in order to control the clinical
course of their disease [21, 43–46]. These patients are more
likely to be hospitalized, undergo additional work-ups, and
refer to higher level medical centers for diagnostic and thera-
peutic approaches [47–49]. This phenomenonmay explain the
higher rate of CVID comparing to selective IgA deficiency in
countries with a hospital based and voluntary registry system.
There was a significant increase in the number of patients
diagnosed with selective IgA deficiency. Before 2006, only 55
cases of this disorder were registered in IPIDR, while 55 new
cases were included in the 7 years period of time afterwards.
This trend is mainly due to the collaborations with other
specialties in the field of research resulting in an increased
awareness [13].
The male to female ratio of the study population was
1.65:1, similar to the previous IPIDR report in 2006 (1.7:1).
This finding which is in agreement with previous reports on
PID [21, 26–30] is probably due to the presence of several
disorders with an X-linked pattern of inheritance such as
XLA, X-linked SCID, X linked Hyper IgM syndrome, X
linked lymphoproliferative diseases and Wiskott-Aldrich syn-
drome. Consanguineous marriage of parents was observed in
63.1 % of cases, lower than the previous report of 2006
(68.5 %), but still much higher than the overall consanguinity
rate of the country’s population (38.6 %) [50]. Consanguinity
is considered to be associated with occurrence of PID, espe-
cially in disorders with autosomal recessive pattern of inher-
itance [11, 50, 51]. Moreover, it may affect the clinical phe-
notypes and onset of disease in disorders such as CVID [51,
52]. Although educational programs via multiple mediaTa
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methods are being already generated, cultural roots of this
type of marriage remained as an obstacle in reducing the
probable burden of these marriages’ outcome. In fact, despite
many efforts in the field of family education, consanguineous
marriages are frequently observed even in the relatives of
some registered Iranian PID patients. Family history of death
at an early age without a known cause was observed in 26.1 %
of our cases. It is likely that the majority of these cases also
suffered from PID but did not undergo mandatory diagnostic
approaches for a definitive diagnosis.
Most of the cases diagnosed with PID are children [11]. In
accordance with other studies, most of our cases were diag-
nosed in childhood and about 60%were diagnosed by the age
of 2 years. Early diagnosis and management of PID can result
in decreased rate of morbidity and mortality, and a higher
quality of life in PID patients [13, 53, 54]. There was a reverse
association between the birth year of patients and the diag-
nostic delay showing a decreased diagnostic delay in the
previous years. A same association was also observed in the
previous report of IPIDR and also in the registry report of
France over a 30 years period of time [11, 28]. Registration of
Iranian PID patients might have played a main role in reduc-
ing the diagnostic delay since it increased the awareness of
medical staff regarding such disorders as well as providing
mandatory diagnostic techniques to cover a larger portion of
the country’s population [11, 55]. Moreover, training of new
clinical immunologists in the country and national wide media
programs specially in immunology week are other factors
resulting in an increased awareness of PID among Iranian
population [13, 56].
The mortality rate of our study population was 18.7 %
similar to the previous report of IPIDR in 2006 with a mor-
tality rate of 17.2 %. It should be kept in mind that the true
mortality rate in the follow-up period may be higher since
patients who did not refer for follow-up or could not be
located at the end of the study are more likely to be dead than
the followed patients [57], especially in disorders like SCID
with a severe and rapid course of disease. Iranian SCID
patients suffer a high mortality rate due to the lack of enough
bone marrow transplantation facilities and matched donors.
Moreover, the short duration of follow-up could result in
underestimation of mortality and should be compared to stud-
ies with a similar duration of follow-up. In fact, it is most
likely that the mortality rate of this study is much higher than
the previous report of 30 years from Iran due to its shorter
follow-up period. Comparing the results of this study with
other reports with a similar follow-up period, Wang et al.
reported a mortality rate of 12.3 % in a study on Chinese
PID patients during 2004 to 2009 [25]. Rhim et al. reported a
mortality rate of 9.8 % among Korean PID patients during
100
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2001 to 2005 [29]. Al-Herz et al. also reported a mortality rate
19.7 % in their study on Kuwaiti PID patients registered
during 2004 to 2006 [31]. Although such studies demonstrat-
ed a similar mortality rate comparing to the current study, an
accurate assessment of the outcome of PID in Iranian patients
can only be achieved after establishing a national wide system
for registration of death certifications similar to some coun-
tries such as Australia [21, 58].
Conclusion
Registration of Iranian PID patients has increased the aware-
ness of Iranian medical community regarding such rare disor-
ders resulting in reduced diagnostic delay. Providing diagnos-
tic and therapeutic methods for a larger portion of the
country’s population necessitates the enrollment of more con-
tributing medical centers especially in areas of need. This step
is also mandatory for a more accurate epidemiologic evalua-
tion of PID in Iran.
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